Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1987 1
1992 1
1993 2
1994 5
1995 1
1996 2
1998 7
1999 1
2000 4
2001 2
2002 4
2003 5
2004 9
2005 11
2006 14
2007 13
2008 15
2009 13
2010 6
2011 12
2012 21
2013 21
2014 18
2015 20
2016 31
2017 21
2018 26
2019 23
2020 24
2021 19
2022 25
2023 23
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA, Caridà G, Ciliberto D, d'Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P. Siciliano MA, et al. Among authors: tassone p. ESMO Open. 2022 Jun;7(3):100465. doi: 10.1016/j.esmoop.2022.100465. Epub 2022 Apr 12. ESMO Open. 2022. PMID: 35427835 Free PMC article.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Chan A, et al. Among authors: tassone p. Lancet Oncol. 2016 Mar;17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10. Lancet Oncol. 2016. PMID: 26874901 Clinical Trial.
Mir-34: a new weapon against cancer?
Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Misso G, et al. Among authors: tassone p. Mol Ther Nucleic Acids. 2014 Sep 23;3(9):e194. doi: 10.1038/mtna.2014.47. Mol Ther Nucleic Acids. 2014. PMID: 25247240 Free PMC article. Review.
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
Nardone V, Romeo C, D'Ippolito E, Pastina P, D'Apolito M, Pirtoli L, Caraglia M, Mutti L, Bianco G, Falzea AC, Giannicola R, Giordano A, Tagliaferri P, Vinciguerra C, Desideri I, Loi M, Reginelli A, Cappabianca S, Tassone P, Correale P. Nardone V, et al. Among authors: tassone p. Radiol Med. 2023 Mar;128(3):316-329. doi: 10.1007/s11547-023-01602-z. Epub 2023 Feb 14. Radiol Med. 2023. PMID: 36786970 Free PMC article. Review.
Mir-221/222 are promising targets for innovative anticancer therapy.
Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: tassone p. Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Expert Opin Ther Targets. 2016. PMID: 26959615 Review.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: tassone p. Crit Rev Oncol Hematol. 2024 Jan;193:104229. doi: 10.1016/j.critrevonc.2023.104229. Epub 2023 Dec 7. Crit Rev Oncol Hematol. 2024. PMID: 38065404 Free article. Review.
The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: tassone p. Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Expert Rev Hematol. 2018. PMID: 30148649 Review.
371 results